Alyeska Investment Group L.P. Buys Shares of 186,222 Sionna Therapeutics, Inc. $SION

Key Points

• Alyeska Investment Group L.P. acquired a new position in Sionna Therapeutics, Inc., purchasing 186,222 shares valued at approximately $1.95 million.
• Other significant investments in Sionna Therapeutics include RA Capital Management L.P. acquiring about $109 million worth of shares, indicating strong institutional interest.
• Analysts have given Sionna Therapeutics a consensus rating of "Buy" and a price target averaging $36.00, with some predicting a target as high as $45.00.

Alyeska Investment Group L.P. acquired a new stake in Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 186,222 shares of the company's stock, valued at approximately $1,948,000. Alyeska Investment Group L.P. owned approximately 0.42% of Sionna Therapeutics as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. RA Capital Management L.P. purchased a new position in Sionna Therapeutics in the 1st quarter worth approximately $109,258,000. TPG GP A LLC purchased a new stake in Sionna Therapeutics in the 1st quarter worth approximately $69,925,000. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Sionna Therapeutics in the 1st quarter worth approximately $38,639,000. Jennison Associates LLC bought a new stake in shares of Sionna Therapeutics in the 1st quarter worth approximately $8,995,000. Finally, Aberdeen Group plc bought a new position in shares of Sionna Therapeutics during the first quarter valued at approximately $7,803,000.

Analyst Ratings Changes

Several research analysts have recently issued reports on SION shares. Raymond James Financial initiated coverage on Sionna Therapeutics in a research report on Tuesday, September 2nd. They issued a "strong-buy" rating and a $45.00 target price for the company. Jones Trading started coverage on shares of Sionna Therapeutics in a report on Monday. They set a "buy" rating and a $46.00 target price on the stock. Royal Bank Of Canada started coverage on shares of Sionna Therapeutics in a research report on Wednesday, September 3rd. They issued a "sector perform" rating and a $22.00 target price on the stock. Finally, Wall Street Zen raised shares of Sionna Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $38.00.

Insider Buying and Selling

In related news, major shareholder Tpg Gp A, Llc purchased 60,000 shares of Sionna Therapeutics stock in a transaction dated Friday, June 27th. The stock was purchased at an average cost of $15.84 per share, for a total transaction of $950,400.00. Following the completion of the purchase, the insider directly owned 6,744,962 shares of the company's stock, valued at $106,840,198.08. The trade was a 0.90% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Elena Ridloff sold 8,836 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $25.08, for a total transaction of $221,606.88. Following the transaction, the chief financial officer directly owned 38,532 shares of the company's stock, valued at $966,382.56. The trade was a 18.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,000 shares of company stock worth $1,466,671. 3.90% of the stock is owned by corporate insiders.

Sionna Therapeutics Trading Down 4.8%

Shares of NASDAQ SION traded down $1.18 during midday trading on Wednesday, hitting $23.32. The stock had a trading volume of 204,744 shares, compared to its average volume of 198,524. The business's 50 day moving average is $20.81 and its 200-day moving average is $16.03. Sionna Therapeutics, Inc. has a 52 week low of $7.26 and a 52 week high of $26.50.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.27.

Sionna Therapeutics Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.